Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Verrier

Showing results (81-90 of 131) with videos related to

Pageof 14
Sort By:
Vaccine|October 2, 2007
Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbitsChristophe Guillon, Katia Mayol, Céline Terrat, et al.
The Journal of Investigative Dermatology|December 16, 2011
Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responsesChristelle Liard, Séverine Munier, Alix Joulin-Giet, et al.
Molecules (Basel, Switzerland)|December 23, 2022
Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania MajorSana Ayari-Riabi, Noureddine Ben Khalaf, Balkiss Bouhaouala-Zahar, et al.
AIDS (London, England)|May 23, 2013
Secretory IgA specific for MPER can protect from HIV-1 infection in vitroFahd Benjelloun, Reham Dawood, Silvio Urcuqui-Inchima, et al.
Protein Expression and Purification|May 24, 2015
A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in celluloSophie Legaz, Jean-Yves Exposito, Agnès Borel, et al.
Antiviral Research|December 10, 2022
Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virusMyriam Lamrayah, Fanny Charriaud, Manon Desmares, et al.
Molecules (Basel, Switzerland)|June 28, 2023
Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph NodesMyriam Lamrayah, Capucine Phelip, Renaud Rovera, et al.
Vaccine|May 11, 2011
Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responsesChristelle Liard, Séverine Munier, Mauricio Arias, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 22, 2006
Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicityDelphine Lamalle-Bernard, Séverine Munier, Christelle Compagnon, et al.
Pharmaceutical Research|June 18, 2009
Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapyFiorenza Rancan, Dimitrios Papakostas, Sabrina Hadam, et al.
Pageof 14

Showing results (81-90 of 131) with videos related to

Sort By:
Pageof 14
Vaccine|October 2, 2007
Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbitsChristophe Guillon, Katia Mayol, Céline Terrat, et al.
The Journal of Investigative Dermatology|December 16, 2011
Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responsesChristelle Liard, Séverine Munier, Alix Joulin-Giet, et al.
Molecules (Basel, Switzerland)|December 23, 2022
Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania MajorSana Ayari-Riabi, Noureddine Ben Khalaf, Balkiss Bouhaouala-Zahar, et al.
AIDS (London, England)|May 23, 2013
Secretory IgA specific for MPER can protect from HIV-1 infection in vitroFahd Benjelloun, Reham Dawood, Silvio Urcuqui-Inchima, et al.
Protein Expression and Purification|May 24, 2015
A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in celluloSophie Legaz, Jean-Yves Exposito, Agnès Borel, et al.
Antiviral Research|December 10, 2022
Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virusMyriam Lamrayah, Fanny Charriaud, Manon Desmares, et al.
Molecules (Basel, Switzerland)|June 28, 2023
Poloxamers Have Vaccine-Adjuvant Properties by Increasing Dissemination of Particulate Antigen at Distant Lymph NodesMyriam Lamrayah, Capucine Phelip, Renaud Rovera, et al.
Vaccine|May 11, 2011
Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responsesChristelle Liard, Séverine Munier, Mauricio Arias, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 22, 2006
Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicityDelphine Lamalle-Bernard, Séverine Munier, Christelle Compagnon, et al.
Pharmaceutical Research|June 18, 2009
Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapyFiorenza Rancan, Dimitrios Papakostas, Sabrina Hadam, et al.
Pageof 14